Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GNRX VanEck Vectors Generic Drugs ETF (GNRX) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock Analysis About VanEck Vectors Generic Drugs ETF (NASDAQ:GNRX) 30 days 90 days 365 days Advanced Chart Remove Ads Get GNRX alerts:Sign Up Key Stats Today's Range$22.42▼$22.4250-Day Range$22.42▼$22.4252-Week Range$20.17▼$26.19Volume4 shsAverage Volume1,310 shsMarket Capitalization$3.36 millionAssets Under Management$3.36 millionDividend Yield0.04%Net Expense Ratio0.57%Aggregate RatingN/A ETF OverviewRead More… Remove Ads VanEck Vectors Generic Drugs ETF ExpensesTypeGNRXHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.56%0.52%0.53%Other Expenses2.44%0.30%0.50%0.45%0.53%Total Expense2.94%0.70%0.72%0.67%0.71%Fee Waiver-2.37%-0.45%-0.50%-0.31%-0.55%Net Expense0.57%0.61%0.63%0.61%0.60% Receive GNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Vectors Generic Drugs ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNRX ETF News HeadlinesAmplify Weight Loss Drug & Treatment ETF (THNR)August 4, 2024 | finance.yahoo.comVanEck Vectors Preferred Securities Ex Financials ETF declares monthly distribution of $0.1422December 4, 2023 | msn.comTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…March 11, 2025 | Porter & Company (Ad)GDIG ETF Stock Price HistoryNovember 10, 2023 | investing.comVanEck Announces Changes to ETF Product LineApril 18, 2023 | finance.yahoo.comVanEck AEX UCITS ETF (TDT)March 3, 2023 | investing.comSee More Headlines GNRX ETF - Frequently Asked Questions What other stocks do shareholders of VanEck Vectors Generic Drugs ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Vectors Generic Drugs ETF investors own include SLR Investment (SLRC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX) and Yamana Gold (AUY). Fund Details IssuerVan Eck Fund NameVanEck Vectors Generic Drugs ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNRX Inception Date1/12/2016 Fund ManagerHao-Hung (Peter) Liao, Guo Hua (Jason) Jin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkIndxx Global Generics & New Pharma Index CategorySector FocusHealth Care Development LevelBlended Development RegionGlobal Number of Holdings0 Fund Statistics Assets Under Management$3.36 million Average Daily Volume$591.00 Discount/Premium-0.42% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianThe Bank of New York Mellon Corporation DistributorVan Eck Securities Corporation Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCantor Fitzgerald Miscellaneous Outstanding Shares150,000BetaN/A 10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report GNRX Sector ExposureGNRX Industry Exposure This page (NASDAQ:GNRX) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Vectors Generic Drugs ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Vectors Generic Drugs ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNRX Stock Alerts